COMMUNIQUÉ DE PRESSE
News
-
-
COMMUNIQUÉ DE PRESSE
NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024
Nanobiotix to host virtual KOL event discussing NBTXR3 combined with immunotherapy in head and neck cancer and beyond on June 18, 2024 -
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy
Nanobiotix announces new data from Study 1100 showing disease control and tumor response in patients with R/M HNSCC treated with RT-activated NBTXR3 followed by anti-PD-1. Investor event scheduled on June 2nd -
